Crossmark

Clinical efficacy and safety of asciminib in chronic myeloid leukemia-chronic phase (CML-CP) in real-world settings: a systematic literature review

Published Online: 2026-08-20

Authors

Kaushik, Nitin

Gopalan, Greeshma

Misto, Alessandra

Pierro, Mariangela

Valsecchi, Diletta

Breccia, Massimo
License Information

Text and Data Mining valid from 2026-08-20

Accepted Manuscript valid from 2026-08-20
More Information

Article History

Received: 18 February 2026

Accepted: 13 August 2026

First Online: 20 August 2026

Declarations

Ethics approval and consent to participate: Not applicable.

Consent for publication: Not applicable.

Competing interests: NK, GG, AM, MP, DV are Novartis employees. MB: honoraria by Novartis, Incyte, BMS, AOP, Abbvie, Otsuka, GSK, Servier, Takeda.

Document is current